Monitoring Efficacy of Radiotherapy in Lung Cancer and Esophageal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04014465|
Recruitment Status : Recruiting
First Posted : July 10, 2019
Last Update Posted : July 12, 2019
Lung cancer, one of the malignant tumors which poses a threat to human's health, has increased morbidity and mortality recently. Radiotherapy, as one of the common treatments, has important value in clinical application. Esophageal cancer, one of the most common digestive system cancers, has poor prognosis and high mortality. Esophageal cancer has high aggressive and many patients can't get surgical treatment because of the tumor metastasis at the time of diagnosis.Currently, chemoradiotherapy has become one of the standard treatment regimens for patients with unresectable esophageal cancer in National Comprehensive Cancer Network(NCCN). So radiotherapy is one of the most important treatments in esophageal cancer.
Currently, the efficacy evaluation method of radiotherapy is by imaging examination after several courses of treatment. However, new reports suggest that circulating tumor DNA(ctDNA) has the potential to be an indicator of therapeutic effectiveness and recurrence risk.
|Condition or disease|
|Lung Cancer Esophageal Cancer|
Circulating free DNA (cfDNA) can be found dissolved in plasma and serum, at variable amounts. In the case of cancer patients, ctDNA is a fraction of the cfDNA derived from tumor. Currently, the ctDNA is widely used in "liquid biopsy" for not only does it carry the same somatic alterations as the tumor itself but also its percentage is correlated with tumor burden.
This study will investigate the clinical value of efficacy evaluation and prognosis of ctDNA detecting technique in patients with radiotherapy.
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Monitoring Efficacy of Radiotherapy Based on Next Generation Sequencing Liquid Biopsy Technique in Lung Cancer and Esophageal Cancer: a Prospective Study|
|Actual Study Start Date :||February 1, 2019|
|Estimated Primary Completion Date :||June 30, 2022|
|Estimated Study Completion Date :||December 1, 2022|
patients with radiotherapy
The patients of lung cancer or esophagueal cancer, who received definitvie RT, should included in this Cohort.
- progression free survival [ Time Frame: 3 years ]the rate of progression free survival for 3 years
- overall survival [ Time Frame: 3 years ]the rate of overall survival for 3 years
- Adverse Events [ Time Frame: 3 years ]Number of Participants with Adverse Events
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04014465
|Contact: Nan Bi, Doctorfirstname.lastname@example.org|
|Contact: Tao Zhang, Professoremail@example.com|
|Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical sciences||Recruiting|
|Beijing, Beijing, China, 100021|
|Contact: Department of Radiation Oncology|